Treatment Plan
Impression
- RHC indicates general improvement in hemodynamic parameters, particularly a decrease in PVR associated with an associated increase in CO.
- Patient is now considered low risk based on REVEAL 2.0 score of 5 and 2022 ESC/ERS risk score of 1.3 (1.0).
- These findings are consistent with data from the FREEDOM-EV study, which included 690 patients with PAH on background monotherapy.
- Orenitram demonstrated significant improvements in risk status as measured by the French Noninvasive Method (a subset of 2022 ESC/ERS risk parameters) and REVEAL 2.0 risk scores.
Treatment Plan
Continue titrating Orenitram as needed to achieve desired clinical response and tolerability.
- Schedule return visit for 3 months with Echo, NT-proBNP, and 6MWD assessments.